Abstract: Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3? or C4? modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

Abstract: A polymer composition that comprises an olefinic polymer, a flame retardant that includes a halogen-free mineral filler, and a compatibilizing agent is provided. The halogen-free mineral filler constitutes from about 20 wt. % to about 80 wt. % of the composition. The composition may exhibit a degree of water uptake of about 5 wt. % or less after being immersed in water for seven days at a temperature of 23° C.

Abstract: Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3? or C4? modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

Abstract: Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3? or C4? modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

Abstract: Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3? or C4? modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

Abstract: A polymer composition that comprises an olefinic polymer, a flame retardant that includes a halogen-free mineral filler, and a compatibilizing agent is provided. The halogen-free mineral filler constitutes from about 20 wt. % to about 80 wt. % of the composition. The composition may exhibit a degree of water uptake of about 5 wt. % or less after being immersed in water for seven days at a temperature of 23° C.

Abstract: A polymer composition that comprises an olefinic polymer, a flame retardant that includes a halogen-free mineral filler, and a compatibilizing agent is provided. The halogen-free mineral filler constitutes from about 20 wt. % to about 80 wt. % of the composition. The composition may exhibit a degree of water uptake of about 5 wt. % or less after being immersed in water for seven days at a temperature of 23° C.

Abstract: Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3? or C4? modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

Abstract: Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3? or C4? modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

Abstract: Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3? or C4? modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

Abstract: A polymer composition that comprises an olefinic polymer, a flame retardant that includes a halogen-free mineral filler, and a compatibilizing agent is provided. The halogen-free mineral filler constitutes from about 20 wt. % to about 80 wt. % of the composition. The composition may exhibit a degree of water uptake of about 5 wt. % or less after being immersed in water for seven days at a temperature of 23° C.

Abstract: Provided are certain derivatives of amphotericin B (AmB) characterized by reduced toxicity and retained anti-fungal activity. Certain of the derivatives are C16 urea derivatives of AmB. Certain of the derivatives are C3, C5, C8, C9, C11, C13, or C15 deoxy derivatives of AmB. Certain of the derivatives include C3? or C4? modifications of the mycosamine appendage of AmB. Also provided are methods of making AmB derivatives of the invention, pharmaceutical compositions comprising AmB derivatives of the invention, and methods of use of AmB derivatives of the invention.

Abstract: Cellulose ester plastics may be formulated to have a depressed melt processing temperatures, improved heat resistance, increased mechanical stability, or some combination thereof. For example, in some instances, a cellulose ester plastic comprising: a cellulose ester at about 20% to about 90% by weight of the cellulose ester plastic; and a plasticizer that comprises a carbonate ester, a polyol benzoate, or both, wherein the plasticizer is at about 2% to about 40% by weight of the cellulose ester plastic, wherein the cellulose ester plastic is melt processable.

Abstract: Cellulose ester plastics may be formulated to have a depressed melt processing temperatures, improved heat resistance, increased mechanical stability, or some combination thereof. For example, in some instances, a cellulose ester plastic may include a plasticized cellulose ester at about 1% to about 99% by weight of the cellulose ester plastic, the plasticized cellulose ester consisting of a cellulose ester at about 60% to about 90% by weight of the plasticized cellulose ester and a plasticizer at about 10% to about 40% by weight of the plasticized cellulose ester, wherein the plasticizer comprises a carbonate ester, a polyol benzoate, or both; and a thermoplastic polymer at about 1% to about 99% by weight of the cellulose ester plastic; and wherein the cellulose ester plastic is melt processable.

Abstract: A process for producing an anti-fog consumer product. The process comprises the steps of forming a precursor composition comprising cellulose acetate and plasticizer to yield a substantially rigid consumer product having an outer surface; and saponifying at least a portion of the substantially rigid consumer product to yield the anti-fog consumer product having a degree of substitution at the outer surface of less than 0.75.